Scarica l'app Stockscreener
2.93
3.17%
0.09
Dopo l'orario di chiusura:
2.90
-0.03
-1.02%
Precedente Chiudi:
$2.84
Aprire:
$2.8
Volume 24 ore:
178.84K
Relative Volume:
1.22
Capitalizzazione di mercato:
$87.20M
Reddito:
-
Utile/perdita netta:
$-13.08M
Rapporto P/E:
-6.635
EPS:
-0.4416
Flusso di cassa netto:
-
1 W Prestazione:
-25.82%
1M Prestazione:
-27.65%
6M Prestazione:
-46.04%
1 anno Prestazione:
-59.92%
Intervallo 1D:
$2.61
$3.08
Intervallo di 1 settimana:
$2.61
$4.005
Portata 52W:
$2.61
$9.39
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Nome
Telomir Pharmaceuticals Inc
Settore
Industria
Telefono
786-396-6723
Indirizzo
100 SE 2ND ST, MIAMI
Confronta TELO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
2.93 | 87.20M | 0 | -13.08M | 0 | -0.4416 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-21 | Iniziato | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Borsa (TELO) Ultime notizie
Charles Schwab Investment Management Inc. Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
TELO stock touches 52-week low at $3.1 amid market challenges By Investing.com - Investing.com South Africa
TELO stock touches 52-week low at $3.1 amid market challenges - Investing.com
Virtu Financial LLC Acquires Shares of 14,959 Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Bank of New York Mellon Corp Increases Stock Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Analyzing Telomir Pharmaceuticals (TELO) & The Competition - Defense World
Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells - Bluefield Daily Telegraph
Telomir Pharmaceuticals announces anti-cancer effects in prostate cancer animal model - MSN
SWK Holdings Announces Monetization of Royalty Portfolio - Waco Tribune-Herald
Telomir-1 shows promise in cancer and chemotherapy study By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals Says Telomir-1 Reduces Tumor Size in Prostate Cancer Animal Model - MarketScreener
Telomir-1 shows promise in cancer and chemotherapy study - Investing.com
Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports breakthrough in prostate cancer treatment - Investing.com India
Breakthrough: New Cancer Drug Cuts Prostate Tumors by Half While Reducing Chemo Toxicity - StockTitan
Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows - Benzinga
Rhumbline Advisers Boosts Position in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) - Defense World
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 34.4% in February - Defense World
Telomir-1 shows promise in reversing cell aging By Investing.com - Investing.com South Africa
Telomir-1 shows promise in reversing cell aging - Investing.com India
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines - Eagle-Tribune
Could This Anti-Aging Compound Revolutionize Treatment for Alzheimer's and Macular Degeneration? - StockTitan
Telomir Pharmaceuticals announces Telomir-1 reverses calcium dysregulation in multiple human cell lines - MSN
Telomir Pharmaceuticals reports key preclinical success By Investing.com - Investing.com South Africa
Telomir Pharmaceuticals reports key preclinical success - Investing.com India
Telomir Pharmaceuticals achieves breakthrough in silver ion stabilization - MSN
Telomir Pharmaceuticals (NASDAQ:TELO) Research Coverage Started at Rodman & Renshaw - Defense World
Telomir-1 exhibited strong ROS reduction properties, hold potential for AMD treatment - Ophthalmology Times
Telomir reports stabilization of silver forms for medical use By Investing.com - Investing.com Nigeria
Telomir Pharmaceuticals Says Telomir-1 Compound Stabilizes Silver for Advanced Medical Applications - Marketscreener.com
Telomir reports stabilization of silver forms for medical use - Investing.com
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market - Weatherford Democrat
Telomir Pharmaceuticals announces silver ion breakthrough - Investing.com
Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration - Benzinga
TELO Again Announces Breakthrough Results - MSN
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD) - Milton Daily Standard
What is Zacks Small Cap's Estimate for TELO Q1 Earnings? - MarketBeat
Telomir Pharmaceuticals (NASDAQ:TELO) Announces Earnings Results, Misses Estimates By $0.05 EPS - MarketBeat
What is Zacks Small Cap’s Estimate for TELO Q1 Earnings? - Defense World
Telomir Pharmaceuticals Inc. (TELO) reports earnings - Quartz
TELO Treatment Amazes in Preclinical Trial - MSN
Will These 5 Big Drug Stocks Surpass Q4 Earnings Forecasts? - Barchart
Telomir Pharmaceuticals Announces Major Breakthrough in Reversing Oxidative Stress, Unlocking Potential for Treating Age-Related Diseases and Viruses Like Bird Flu - Barchart
Telomir Pharmaceuticals Inc Azioni (TELO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):